Can Ivosidenib treat glioma?

Ivosidenib (Ivosidenib) is mainly studied and used to treat acute myeloid leukemia (AML), especially those expressing IDH1 gene mutations. However, research into its use in treating other types of cancer, including glioma, is also ongoing.

Glioma is a malignant tumor that occurs in the central nervous system, usually in the brain or spinal cord. IDH1gene mutations are also relatively common mutations in some gliomas. Therefore, researchers are interested in whether IDH1 inhibitors, such as ivonib, have potential efficacy in treating certain types of glioma.

Some preliminary research results suggest that IDH1 inhibitors may show some therapeutic effect in some glioma patients. Such trials typically involve genetic testing of patients to determine whether their tumors carry IDH1 mutations and then placing them on treatment with IDH1 inhibitors. However, research in this area is still in its early stages and more clinical trials are needed to evaluate its safety and effectiveness.

It should be emphasized that the indications and efficacy of drugs may change as research progresses. If you or someone you care about has glioma, it is recommended to speak with a medical professional to get detailed information about the latest treatment options and to determine if there are any clinical trials available for your specific case.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.